differ
assay
use
analyz
serum
specimen
collect
militari
recruit
peopl
republ
china
sever
acut
respiratori
syndrom
sar
coronaviru
antibodi
result
demonstr
subject
either
rare
expos
viru
sar
outbreak
expos
nucleocapsid
protein
crossreact
antibodi
human
midnovemb
first
case
uniqu
atyp
infecti
pneumonia
found
foshan
citi
guangdong
provinc
peopl
republ
china
diseas
spread
throughout
mani
area
china
region
countri
around
world
world
health
organ
recogn
sever
acut
respiratori
syndrom
sar
may
whocoordin
scientif
team
identifi
novel
coronaviru
sar
coronaviru
sarscov
caus
agent
sar
natur
reservoir
sarscov
discov
although
sarscovlik
virus
isol
himalayan
palm
civet
evid
viru
infect
also
document
anim
includ
raccoon
dog
nyctereut
procyonoid
human
retail
market
guangdong
provinc
china
use
immunofluoresc
neutral
assay
zheng
et
al
detect
antibodi
human
sarscov
andor
anim
sarscovlik
viru
healthi
adult
hong
kong
suggest
small
proport
healthi
peopl
hong
kong
expos
sarsrel
virus
least
year
first
sar
outbreak
studi
investig
whether
peopl
mainland
china
expos
sarscov
first
sar
outbreak
serum
sampl
screen
enzymelink
immunosorb
assay
elisa
posit
sampl
analyz
variou
serolog
assay
serum
sampl
taken
healthi
militari
recruit
routin
examin
march
year
first
sar
outbreak
serum
sampl
store
sarscovrel
analysi
soldier
came
provinc
includ
guangdong
provinc
china
men
whose
health
statu
met
standard
armi
recruit
addit
posit
control
serum
sampl
taken
patient
clinic
confirm
sar
beij
neg
control
serum
sampl
collect
healthi
volunt
serum
sampl
heat
inactiv
min
analysi
first
screen
use
elisa
kit
beij
gbi
biotechnolog
co
ltd
detect
immunoglobulin
g
igg
antibodi
sarscov
wholeviru
lysatebas
kit
elisa
kit
approv
china
state
food
drug
administr
sarscov
antibodi
detect
sar
outbreak
frequent
use
assay
mainland
china
eleven
serum
sampl
posit
igg
antibodi
sarscov
elisaposit
sampl
test
immunofluoresc
assay
ifa
neutral
assay
specif
elisa
four
hundr
elisaneg
serum
sampl
also
randomli
select
confirm
result
ifa
result
show
neg
ifa
ifa
perform
use
ifa
kit
approv
use
china
state
food
drug
administr
sar
outbreak
manufactur
institut
microbiolog
epidemiolog
academi
militari
medic
scienc
beij
neutral
assay
serum
sampl
serial
dilut
mix
time
tissu
cultur
infect
dose
sarscov
incub
h
mixtur
inocul
onto
vero
cell
monolay
plate
well
use
dilut
result
determin
incub
tabl
show
elisaposit
sampl
posit
igg
antibodi
ifa
howev
neg
neutral
assay
find
differ
describ
previou
report
zheng
et
al
sampl
individu
hong
kong
explor
reason
differ
find
use
protein
microarray
screen
specif
antibodi
individu
protein
sarscov
nucleocapsid
n
proteinbas
antigencaptur
elisa
confirm
result
antin
antibodi
previou
report
protein
microarray
assay
perform
detect
igg
antibodi
individu
protein
sarscov
briefli
recombin
protein
associ
structur
protein
e
n
put
uncharacter
protein
sarscov
prepar
use
screen
serum
sampl
convalescentphas
sar
patient
igg
antibodi
specif
protein
use
protein
microarray
cutoff
valu
fluoresc
intens
protein
calcul
use
fluoresc
intens
valu
protein
normal
human
serum
antibodi
protein
n
detect
sera
convalescentphas
sar
patient
wherea
antibodi
protein
e
detect
present
studi
protein
microarray
describ
appli
elisaposit
serum
specimen
among
recombin
protein
n
protein
react
sampl
wherea
sampl
neg
antibodi
main
antigen
protein
sarscov
tabl
result
reveal
protein
microarray
analysi
confirm
n
proteinbas
antigencaptur
elisa
tabl
recombin
fulllength
n
proteinbas
elisa
kit
sinoamerican
bioengin
co
could
detect
total
antibodi
igg
igm
iga
etc
n
protein
sarscov
antin
anti
antibodi
prove
first
second
frequent
antibodi
respect
sera
sar
patient
howev
among
structur
protein
protein
identifi
signific
neutral
antigen
protect
antigen
antin
antibodi
lack
neutral
activ
present
studi
elisaposit
sampl
neg
neutral
assay
although
least
three
sampl
posit
test
find
suggest
two
possibl
first
recruit
might
expos
sarscov
sarscovlik
viru
first
sar
outbreak
contrast
report
zheng
et
al
sera
peopl
neg
neutral
assay
reason
like
concentr
neutral
antibodi
anti
antibodi
low
neutral
viru
detect
antin
antibodi
lack
neutral
activ
although
exposur
histori
symptom
particip
studi
unavail
assess
exist
subclin
nonpneumon
sarscov
infect
possibl
second
none
recruit
expos
sarscov
posit
result
elisa
ifa
protein
microarray
analysi
antigencaptur
elisa
might
fals
posit
sinc
elisa
ifa
kit
use
studi
first
second
frequent
use
sar
outbreak
mainland
china
respect
presenc
possibl
falseposit
result
indic
result
obtain
kit
combin
result
obtain
diagnost
test
clinic
sign
symptom
diagnosi
sar
use
recombin
nproteinbas
protein
microarray
assay
antigencaptur
elisa
could
reduc
probabl
falseposit
result
possibl
crossreact
sarscov
n
protein
antibodi
human
also
taken
account
specif
recombin
truncat
n
protein
potenti
candid
antigen
protein
could
screen
develop
use
reliabl
serolog
assay
conclus
result
suggest
peopl
mainland
china
either
rare
expos
sarscov
sar
outbreak
expos
sarscov
sarscov
n
protein
crossreact
antibodi
human
need
verifi
